MFS Medifocus Inc

NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

Medifocus Inc. (TSX VENTURE:MFS)(OTCQX:MDFZF) (Medifocus or the Company) is
pleased to announce the election of Mr. Tak Cheung Yam as a member of the Board
of Directors of the Company at the Company's annual and special meeting held on
November 28, 2012. In addition, incumbent directors Messrs. Augustine Y. Cheung,
Joseph S.C. Chan, Augustine P.Y. Chow, Ernie Eves and Grant B. Walsh (Chairman)
were also re-elected. 


Mr. Yam, B.Sc. has been the Chairman, Executive Director and Co-Founder of
Fornton Group Limited (HKEX) since October 11, 2011. Mr. Yam has participated in
various charitable activities of Yan Oi Tong, one of the six largest charitable
organizations in Hong Kong and was appointed as the Chairman of Yan Oi Tong in
2007. Subsequently, he was awarded a Medal of Honor from the HKSAR Government.
Mr. Yam advocated the establishment of YOT Chong Sok Un Medical Fund (Cancer
Aid) in 2007, which is now the largest cancer fund in Hong Kong. 


"I am delighted to welcome TC to our Board and look forward to working with
him," said Mr. Grant Walsh, the Chairman of the Board of Directors of Medifocus.
"TC's extensive experience in financial industry and his dedication to cancer
treatment will benefit Medifocus tremendously in its future growth, particularly
in the Asia Pacific region." Mr. Yam commented, "I am attracted to Medifocus by
its team's dedication to the development of advanced microwave technology to
treat cancers and other diseases. I look forward to applying my experience and
providing my insights as Medifocus continues to capitalize on its proprietary
technology platforms." 


For the quarter ended September 30, 2012, Medifocus reported its first ever
revenue of $313,281 from sales of its Prolieve(R) System. Dr. Augustine Y.
Cheung, President and CEO of the Company commented: "We are pleased with the
revenue achieved in the short transitional period after the Company acquired the
Prolieve(R) business and we expect sales from Prolieve(R) will accelerate once
the transition is completed. We have assembled a seasoned sales and service team
and are gaining our customers' confidence in Prolieve(R) and the continuous
product and service support by Medifocus." 


Medifocus develops and commercializes minimally invasive heat treatment systems
used in treatment of cancerous and benign tumors, and enlarged prostate, Benign
Prostatic Hyperplasia ("BPH"). 


The Company owns two technology platforms with comprehensive US and
international patent protection: The "Endo-thermotherapy Platform" and the
"Adaptive Phased Array Microwave Focusing Platform". The Company has developed
two advanced therapeutic products: the Adaptive Phased Array (APA)-1000 system
for treatment of breast cancer and the Prolieve(R) system for the treatment of
BPH. The APA-1000 uses precisely focused and controlled microwave energy to
shrink breast cancer tumors without side-effects on the surrounding tissues to
produce better treatment outcomes. The Company has received regulatory approvals
to complete the APA 1000's pivotal Phase-III clinical trials, the final step
before marketing approval. The U.S. FDA-approved Prolieve(R) System
(www.prolieve.com) is a medical device based on endo-thermotherapy that both
heats the prostate and dilates the prostatic urethra. The Prolieve(R) System is
the only minimally invasive treatment option for the symptoms of enlarged
prostate in men indicated by the FDA as an in office treatment alternative to
drug therapy. The Prolieve(R) System is a revenue generating product catering to
the $8 billion non-surgical BPH drug market. The Company is currently focusing
on marketing Prolieve(R) for the treatment of BPH and completing the APA 1000
breast cancer system's Phase III study. For more information, visit
www.medifocusinc.com.


Forward-Looking Statements and Information 

This news release contains "forward-looking statements" and "forward-looking
information", which may not be based on historical facts. Forward-looking
statements and forward-looking information, include, but are not limited to,
information and statements with respect to the benefit to Medifocus's future
growth resulting from the election of Mr. Yam and the expectation that sales
from Prolieve(R) will accelerate. Forward-looking statements are frequently
characterized by words such as "plan," "expect," "project," "intend," "believe,"
"anticipate", "estimate" and other similar words, or statements that certain
events or conditions "may" or "will" occur. Forward-looking statements are based
on the opinions and estimates of management at the date the statements are made.
Such forward-looking statements and forward-looking information involve known
and unknown risks, uncertainties and other factors that may cause the actual
results events or developments to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements or forward-looking information. These factors should be considered
carefully and readers are cautioned not to place undue reliance on such
forward-looking statements and forward-looking information. Except as required
by applicable securities laws, the Company disclaims any obligation to update
any such factors or to publicly announce the results of any revisions to any of
the forward-looking statements or forward-looking information contained herein
to reflect future results, events or developments.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Medifocus Inc.
John Mon
(410) 290-5734
jmon@medifocususa.com

Medifocus (TSXV:MFS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Medifocus (TSXV:MFS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024